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Abstract
Background: Gastrointestinal stromal tumours (GISTs) represent a heterogeneous group of
tumours of mesenchymal origin characterized by gain-of-function mutations in KIT or PDGFRA of
the type III receptor tyrosine kinase family. Although mutations in either receptor are thought to
drive an early oncogenic event through similar pathways, two previous studies reported the
mutation-specific gene expression profiles. However, their further conclusions were rather
discordant. To clarify the molecular characteristics of differentially expressed genes according to
GIST receptor mutations, we combined microarray-based analysis with detailed functional
annotations.
Methods: Total RNA was isolated from 29 frozen gastric GISTs and processed for hybridization
on GENECHIP® HG-U133 Plus 2.0 microarrays (Affymetrix). KIT and PDGFRA were analyzed by
sequencing, while related mRNA levels were analyzed by quantitative RT-PCR.
Results: Fifteen and eleven tumours possessed mutations in KIT and PDGFRA, respectively; no
mutation was found in three tumours. Gene expression analysis identified no discriminative profiles
associated with clinical or pathological parameters, even though expression of hundreds of genes
differentiated tumour receptor mutation and expression status. Functional features of genes
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differentially expressed between the two groups of GISTs suggested alterations in angiogenesis and
G-protein-related and calcium signalling.
Conclusion: Our study has identified novel molecular elements likely to be involved in receptor-
dependent GIST development and allowed confirmation of previously published results. These
elements may be potential therapeutic targets and novel markers of KIT mutation status.
Background
Gastrointestinal stromal tumours (GISTs) arise from pre-
cursor cells shared with the interstitial cells of Cajal (ICC)
[1,2] and encompass a group of heterogeneous neoplasms
with different morphology, biologic behaviour, and
genetic characteristics [3]. Histopathologically, GISTs are
spindle-, epithelioid-, or mixed-cell tumours that usually
develop in the wall of the gastrointestinal tract. GISTs can
be classified as benign, borderline, or malignant tumours
based on tumour size, mitotic index, and the invasion of
surrounding tissues, and the majority of these tumours are
clinically rather non-aggressive [3].
An early oncogenic event in the majority of GISTs is repre-
sented by gain-of-function mutations in either KIT  or
platelet-derived growth factor receptor   (PDGFRA). Both KIT
and PDGFRA belong to the subclass III family of receptor
tyrosine kinases [4-6]. The receptor-activating mutations
lead to self-phosphorylation of a kinase domain, with the
subsequent activation of the JAK/STAT, PI3K/AKT, Ras/
ERK, and PLC-γ intracellular pathways in a ligand-inde-
pendent manner, transmitting mitogenic signals [7-17].
Although mutations in KIT and PDGFRA contribute to
tumour development through similar pathways, they cor-
relate with certain clinicopathological features and differ-
ent responses to imatinib treatment [3]. Moreover, GISTs
with different mutation types exhibit differential gene
expression at the mRNA [18,19] and protein [20] levels.
Two previous studies [18,19] reported differences
between the gene expression profile and pattern of onco-
genic mutations. Both studies and additional analyses
have confirmed the unexpected observation that a muta-
tion of KIT or PDGFRA is associated with its increased
expression at the mRNA level, but in terms of further con-
clusions Subramanian et al. [19] and Kang et al. [18] are
rather discordant. Subramanian and colleagues selected
1875 of almost 28 000 genes or ESTs (expressed sequence
tags) clusters represented on cDNA microarray that passed
filtering criteria and used it for further analysis. Of these
selected genes, 338 were differentially expressed between
GISTs assigned to a KIT exon 11 mutation and other types
of mutations. A total of 270 genes were differentially
expressed between GISTs with a PDGFRA mutation and
other GISTs. Notably, a PDGFRA mutation was observed
in only 8 of 26 analyzed samples.
In contrast, Kang et al. [18], using high-density spotted
oligonucleotide microarrays, selected 4693 out of 18 664
oligonucleotides representing LEADS™ clusters. Among
this set of pre-selected genes, only 70 were differentially
expressed between GISTs exhibiting different mutation
status. Of these 70, Subramanian et al. found only 13
(19%) to be differentially expressed. Both groups reported
that on the basis of gene expression signatures, GISTs har-
bouring different types of mutations could not to be per-
fectly distinguished. Moreover, because of the far-from-
complete coverage of the human genome using the meth-
ods in these studies, only limited functional annotations
were reported. Thus, although these two important stud-
ies have been published, major questions about GIST
biology remain open.
To clarify the molecular characteristics of differentially
expressed genes according to receptor status, we com-
bined microarray-based data with functional annotations.
We selected a model of gastric GIST to obtain a balanced
set of tumours with mutations in either KIT or PDGFRA
[21]. Significant differences in the molecular makeup of
the two groups of gastric GISTs allowed the development
of novel functional hypotheses regarding the transduction
of intracellular signalling contributing to GIST develop-
ment.
Methods
Patients
Between April 2005 and March 2008, 31 patients with a
diagnosis of gastric GIST were prospectively selected for
the study. All patients underwent tumour surgical resec-
tion through laparotomy in the Department of Soft Tis-
sue/Bone Sarcoma and Melanoma, and the final diagnosis
was obtained from the analysis of clinicopathological
findings (Table 1). The study protocol was approved by
the Cancer Center Bioethical Committee, and all patients
signed informed consent before inclusion. The morpho-
logical diagnosis was confirmed by standard H&E staining
and immunoreactivity to KIT (CD117) [22,23] on rou-
tinely formalin-fixed paraffin-embedded specimens. One
to two tumour fragments, depending on tumour size,
were snap frozen and stored at -72°C until use. Then, col-
lections of cryostat sections were prepared from different
parts of each tumour fragment. Upper and lower sections
from each cryosection collection were evaluated by the
pathologist (DJ) to control the relative content of non-BMC Cancer 2009, 9:413 http://www.biomedcentral.com/1471-2407/9/413
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Table 1: Patient clinical, pathological and molecular characteristics of analyzed GIST samples
No Sex Tumour histology Tumour size (mm) Mitotic activity Group Tumour grade CD
117
Mutation
1 Spindle cell 15 0 1 Benign 1 K11:p.573 580dup
2 M Spindle cell 18 2 1 Benign 0 K11:p.571 579(?)dup+
insL(dupins?)
3 F Spindle cell 20 0 2 Benign 1 K11:p.664 676del
4 F Epithelioid 25 2 2 Benign 1 P12:p.566_571delinsR
5 M Spindle cell 28 1 2 Benign 1 K11:p.V559D
6 F Spindle cell 30 2 2 Benign 1 K11: p.W557R
7 M Spindle cell 30 3 2 Benign 1 K11: p.W557R; p.V559D
8 M Spindle cell 35 0 2 Benign 0 P18:p.843 846del
9 M Mixed 35 1 2 Benign 0 P18:p.D842V
10 F Epithelioid 35 1 2 Benign 1 No mutation found
11 M Mixed 40 1 2 Benign 0 P18: p.D842V
12 M Spindle cell 40 1 2 Benign 1 K11:p.578_580dup
13 M Epithelioid 50 2 2 Benign 1 P18: p.843 847delinsL
14 M Spindle cell 53 5 3a Benign 1 K11:p.V559D
15 M Mixed 55 1 3a Benign 1 K9:p.502 503dup
16 M Spindle cell 60 4 3a Benign 1 P18: p.D842V
17 M Mixed 65 0 3a Benign 1 P18:p.843 846del
18 M Spindle cell 65 1 3a Benign 1 K11: p.555 573del
19 M Spindle cell 70 3 3a Benign 1 K11:p.552_556del
20 M Spindle cell 70 4 3a Benign 1 K11: p.V560E
21 M Mixed 80 2 3a Benign 1 P18:p.D842V
22 F Spindle cell 90 2 3a Benign 1 P18:p.D842V
23 M Mixed 90 5 3a Benign 1 No mutation found
24 M Mixed 95 1 3a Benign 1 P12: p.566 571delinsK
25 F Spindle cell 35 13 5 Borderline 1 K11:p.573 585dup+ins C
26 M Mixed 40 7 5 Borderline 0 K11:p.555 556del homoBMC Cancer 2009, 9:413 http://www.biomedcentral.com/1471-2407/9/413
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tumour cells, and the remaining internal portion of the
specimen was used in the study if it contained ≥95%
tumour cells. Genomic DNA from tissue samples was
purified using the DNeasy Tissue Kit, and total RNA was
isolated using the RNeasy Mini Kit (both kits from Qiagen
GmbH, Hilden, Germany).
KIT/PDGFRA genotyping and real-time RT-PCR analysis
DNA samples were tested for hot-spot mutation sites of
KIT (exons 9, 11, 13, 14, and 17) and PDGFRA (exons 12,
14, and 18) by PCR amplification using primers and
annealing temperatures as previously described [24,25].
PCR products were sequenced in two directions by fluo-
rescent dideoxysequencing on an ABI Prism 3100
Sequence Detection System (Applied Biosystems, Foster
City, CA).
Specific RNA concentrations were determined by real-
time reverse transcriptase (RT)-PCR. Total tissue RNA was
isolated with the RNeasy Mini Kit and QIAshredder col-
umns (Qiagen GmbH, Hilden, Germany). Reverse tran-
scription was performed with the SuperScript II Reverse
Transcriptase reagent set (Invitrogen Co., Carlsbad, CA)
according to the manufacturer's instructions. Quantitative
evaluation of mRNA was performed on an ABI Prism
7000 Sequence Detection System with a 25-μl reaction
mixture containing 12.5 μl 2× SYBR Green PCR Master
Mix (Applied Biosystems, Foster City, CA), 5 μl cDNA,
and 50 nM primers. Oligonucleotide primers for the ana-
lyzed KIT/PDGFRA transcripts were designed using Primer
Express Software (Applied Biosystems, Foster City, CA)
and are listed in Supplementary Table S1 (see Additional
file 1). For each run, standard curves were generated for a
primer set by serial dilution of pooled cDNA to counter-
balance variations in PCR reaction efficiency. Melting
curves were generated after each reaction to verify the
melting temperature of the amplicon. In addition, the
purity of the RT-PCR product was verified by agarose gel
electrophoresis. To normalize nonspecific variations in
real-time PCR, the normalization factor was calculated as
the geometric mean of RNA concentrations of three con-
trol genes, glyceraldehyde-3-phosphate dehydrogenase, ubiqui-
tin C, and  -actin.
Gene expression analyses on microarrays
Gene expression profiling was carried out using Affyme-
trix oligonucleotide microarrays (GeneChip HG-
U133plus2) as described previously [26].
To obtain gene expression measurements, the extraction
of probe-level data was performed with a standard GC-
RMA algorithm for background correction and summari-
zation steps and least-variant set algorithm for normaliza-
tion based on a least-variant set of probe sets. The
calculations were performed using BioConductor (version
2.8.1) packages gcrma  (version 2.14.1) and
FLUSH.LVS.bundle (version 1.2.1, proportion = 0.6). To
test the internal consistency of the data sets, we used prin-
cipal component analysis, normalized unscaled standard
error plots, and relative log expression plots.
The measured expression levels were log transformed
(log2). For data filtration, we selected the probe sets exhib-
iting signal intensity above the threshold limit, which was
established at the 95th percentile of the expression levels
from Y-chromosome-linked probe set signals detectable
in female samples. The low-expression (marginal) probe
sets with levels below the threshold in at least 19 samples
were rejected.
To establish gene expression profiles, differentially
expressed probe sets in the pair-wise comparisons were
identified using the Kruskal-Wallis test. The resulting P
values were adjusted for testing of multiple hypotheses
using the Benjamini-Hochberg procedure that controls a
false discovery rate. The false discovery rate threshold was
set to 0.1, and only probe sets exhibiting a minimum two-
fold change in mean relative expression were included in
the gene lists. Cluster analysis of probe sets exhibiting dif-
ferential expression was also performed. The probe sets
were divided into groups of distinct expression patterns by
an evolutionary-driven k-means clustering algorithm with
a distance metric derived from the Pearson correlation
coefficient. Unsupervised average-linkage hierarchical
clustering and PCA were used for a graphic summary and
evaluation of relationships between samples.
Both statistical and clustering analyses were performed
using a proprietary software working in the MATLAB
(MathWorks) and Bioconductor (2.8.1) environments.
Functional analyses of gene expression by Gene Ontology
Differentially expressed probe sets were annotated with
Gene Ontology (GO) terms (GO.db version 2.2.5) using
the Bioconductor packages GOstats  (version 2.8.0,
Affymetrix HG-U133 Plus 2.0 Array Annotation Data) and
package annotate (version 1.20.1). The significance of dif-
27 M Spindle cell 55 7 6a Malignant 0 No mutation found
28 M Spindle cell 70 21 6a Malignant 1 P18:p.D842V
29 M Spindle cell 160 7 6b Malignant 1 K11:p.556 563del
Table 1: Patient clinical, pathological and molecular characteristics of analyzed GIST samples (Continued)BMC Cancer 2009, 9:413 http://www.biomedcentral.com/1471-2407/9/413
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ferential representation of GO terms between specified
lists of probe sets was determined by the hypergeometric
test implemented in GOstats (version 2.8.0). P  values
returned by GOstats were corrected for testing of multiple
hypotheses with the Benjamini-Hochberg method imple-
mented in an R environment (version 2.8.1, The R Foun-
dation for Statistical Computing; http://www.r-
project.org). Adjusted P values of less than 0.1 were con-
sidered significant.
Models of KIT and PDGFRA (a and b subunits) signalling
pathways were prepared on the basis of three databases:
Biogrid (The Biological General Repository for Interaction
Datasets) [27], HPRD (Human Protein Reference Data-
base) [28], and BIND (Biomolecular Interaction Network
Database) [29] and additional literature searches.
Results
KIT and PDGFRA mutation profiling
Gene expression profiles from 29 out of 31 primary gastric
GISTs were selected for the molecular analysis. Two sam-
ples were rejected due to poor quality of extracted infor-
mation after MAS5.0 testing of criteria suggested by the
producer. Of the 29 cases, 24, 2, and 3 cases were classi-
fied as benign (very low or low risk), borderline (interme-
diate risk), and malignant (high risk), respectively (Table
1). Such a distribution is consistent with the general clin-
ical picture of gastric GISTs [21]. Genotyping revealed that
15 tumours had KIT mutations (14 in exon 11 and one in
exon 9), 11 tumours had PDGFRA mutations (9 in exon
18 and two in exon 12), and 3 were KIT/PDGFRA wild-
type GISTs within the analyzed mutation hotspots (Table
1). A total of 23 tumours were CD117/KIT-positive on
immunohistochemistry (IHC). Of these, 13 and 8
tumours had KIT or PDGFRA mutations, respectively. In
addition, two wild-type tumours were also KIT-positive.
Thus, expression of KIT in IHC did not correlate with
receptor tyrosine kinase mutation status (Table 1).
Microarray results and mutation status
From 54 675 probe sets of the Affymetrix HGU133plus2
microarray, 16 880 probe sets passed the filtering proce-
dure. Among the probe sets with detectable expression
levels, the non-parametric Kruskal-Wallis test revealed
970 (311 with FC>2; FC = fold change) probe sets differ-
entially expressed between tumours with KIT and PDG-
FRA mutations. Of these 311 (FC>2), 109 probe sets (81
genes) were upregulated, and 202 probe sets (143 genes)
were downregulated in samples from tumours harbouring
KIT mutations compared to those with PDGFRA muta-
tions. Supplementary Table S2 (see Additional file 1) gives
the complete list of differentially expressed probe sets. As
expected, unsupervised hierarchical clustering (Figure 1)
of differentially expressed genes distinguished GIST sam-
ples according to the mutation status.
As reported previously [18,19], increased expression of
KIT and PDGFRA follows their mutation status. To evalu-
ate the impact of mutation status on expression of genes
encoding both receptors, quantitative RT-PCR analysis
was performed simultaneously on the same RNA samples
used in the microarray analysis. An overall good correla-
tion was observed between quantitative changes in KIT
expression levels obtained by microarrays and quantita-
tive RT-PCR (not shown). However, while the microarray
signal intensity of PDGFRA probe sets was in most arrays
slightly above the threshold limit, RT-PCR allowed for
more reliable quantification of PDGFRA transcript levels.
Overexpression of KIT and PDGFRA was closely related to
receptor mutation status. As shown in Figure 2, in 14 out
of 15 GISTs with a KIT mutation and in 2 out of 10 GISTs
with a PDGFRA mutation, the relative expression of KIT
was 1.47 arbitrary units (a.u.) or greater, while in the
remaining tumours, it was 0.37 a.u. or lower. In contrast,
in nine tumours with a PDGFRA  mutation and one
tumour with a KIT mutation, the expression of PDGFRA
was ≤1.32 a.u., while in the remaining GISTs with KIT/
PDGFRA mutations, it was ≤0.84 a.u. One tumour with a
PDGFRA mutation exhibited overexpression of both KIT
and  PDGFRA. Among receptor wild-type GISTs, the
expression profile for one tumour was typical for tumours
with PDGFRA mutations and was typical in two others for
tumours with a KIT mutation. These findings suggest the
presence of a potential additional region undergoing
oncogenic mutations in both analyzed genes.
When selection of differentially expressed genes was per-
formed according to the discriminating KIT transcript lev-
els, the microarray data from the two groups of 15 and 13
tumour samples with either high or low KIT expression
were included in analyses. At this point, 3116 (680 with
the FC>2) probe sets indicated genes that were differen-
tially expressed. (see Additional file 1: Supplementary
Table S3). Of these, 253 probe sets (171 genes) were
upregulated, and 427 probe sets (299 genes) were down-
regulated in tumours with overexpressed KIT compared to
those with low expression. Again, unsupervised hierarchi-
cal clustering showed that gene expression patterns of the
individual tumour samples from these two groups clus-
tered together (see Additional file 2: Supplementary Fig-
ure S1).
No gene expression signature was found to be associated
with tumour size, mitotic index, or risk category.
Gene enrichment analyzes
Differential expression was then analyzed on the level of
GO categories and KEGG (Kyoto Encyclopedia of Genes
and Genomes) pathways. Functional features of the 311
and 680 genes that differentiated tumours according toBMC Cancer 2009, 9:413 http://www.biomedcentral.com/1471-2407/9/413
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Unsupervised hierarchical clustering for the selection of differentially expressed genes in GIST tumours according to KIT muta- tion Figure 1
Unsupervised hierarchical clustering for the selection of differentially expressed genes in GIST tumours 
according to KIT mutation. Across the top, individual tumour samples are arrayed in a column (upper: blue - KIT mutation; 
red - PDGFRA mutation; gray- no mutation found; lower: green - low KIT expression/high PDGFRA expression; yellow- high KIT 
expression/low PDGFRA expression; dark gray- high KIT/PDGFRA expression); on the left side, 311 individual probe sets differ-
entiating tumours in accordance with the mutation are shown in rows. The colour in each cell reflects the level of expression 
of the corresponding probe set in the corresponding array sample relative to its mean level of expression estimated for the 
entire set of samples. Red indicates expression levels greater than the mean, and green indicates lower than the mean.BMC Cancer 2009, 9:413 http://www.biomedcentral.com/1471-2407/9/413
Page 7 of 10
(page number not for citation purposes)
receptor mutations and expression allowed selection of
respectively nine and seven subcategories, as analyzed by
their annotation to GO terms (see Additional file 1: Sup-
plementary Table S4). Overrepresentation (estimated by
the highest level of significance) was represented by blood
vessel development (GO:0001568),  angiogenesis
(GO:0001525), cell adhesion (GO:0007155), and G-pro-
tein coupled receptor protein signalling pathway
(GO:0007186). Terms that exhibited lower levels of statis-
tical significance were represented by elevation of cytosolic
calcium ion concentration (GO:0007204),  transmembrane
receptor protein tyrosine kinase signalling pathway
(GO:0007169), and cellular calcium ion homeostasis
(GO:0006874). In similar pair-wise comparisons per-
formed for KEGG pathways, differentially regulated path-
ways were represented by calcium signalling pathway and
cytokine-cytokine receptor interaction.
Interestingly, the expression of 7 genes annotated to syn-
aptic transmission, 15 genes annotated to blood vessel
development, and 20 genes annotated to G-protein sig-
nalling were at least 2-fold higher in tumours with low
KIT expression compared to those with high KIT expres-
sion (see Additional file 1: Supplementary Table S5).
Because previous studies indicated that KIT-mutant and
PDGFRA-mutant GISTs may have features associated with
activation of downstream pathways like ERK1/2, AKT,
p70/85S6K, STAT1/STAT3, and PI3K/mTOR [5,7-17], the
lists of differentially expressed genes were compared with
both lists of interacting partners of KIT and PDGFR, sum-
marized in Supplementary Table S5 (see Additional file
1). According to our model of PDGFRA signalling path-
ways, the final data set contained 44 and 52 proteins inter-
acting with KIT and PDGFR, respectively, 13 of which
were common for both pathways (see Additional file 1:
Supplementary Table S6). Within the list of differentially
expressed genes according to the mutation status only 3
genes corresponding to PDGFRA interactome were found.
None of KIT genes encoding KIT-signalling pathway pro-
teins was found within this list.
To further test other pathways described by Corless et al.
[5], we also analyzed genes from selected KEGG pathways
involved in mitogenic signal transduction (mTOR, Jak-
STAT, MAPK, TGF-beta, calcium signalling, vascular
endothelial growth factor (VEGF) signalling). Those genes
were compared with lists of differentially expressed genes
depending on KIT/PDGFRA mutation status. Apart from
protein kinase C (PKC)-alpha, no other genes from such
lists were found among the differentially expressed genes
(data not shown).
Among PKC isoforms analyzed in this study by microar-
ray (alpha, beta isoform 1, variant 1, eta, iota, zeta) and
quantitative RT-PCR (alpha, beta isoform 1, variant 1 and
2, delta, epsilon, theta) (data not shown), expression of
PKC-alpha was significantly lower (FC = 0.17; P  <
0.00016), while expression of PKC-theta was significantly
higher (FC = 2.34; P  < 0.00016) in tumours with KIT
mutations compared to those with PDGFRA mutations
and wild-type tumours.
Discussion
GISTs express KIT, a 145-kD transmembrane glycoprotein
that serves as the receptor for stem-cell factor [30,31]. KIT
activates cellular signalling during embryogenesis [32,33]
and is critical for the development of germ cells, hemat-
opoietic progenitor cells, and mast cells [34]. Its function
is closely related to that of other receptor tyrosine kinases
for PDGF, macrophage colony stimulating factor, and
FLT3 ligand [35]. Activating mutations in the KIT  and
PDGFRA genes result in ligand-independent activation of
their receptor tyrosine kinase function, which may trans-
mit early oncogenic signals in the majority of GISTs
(Rutkowski et al., 2008).
Relative mRNA expression of KIT (left panel) and PDGFRA  (right panel) in GIST tumours according to sample mutation  status Figure 2
Relative mRNA expression of KIT (left panel) and 
PDGFRA (right panel) in GIST tumours according to 
sample mutation status. Black circles - KIT mutations; 
gray circles - PDGFRA mutations
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Even though the biological consequences of KIT  and
PDGFRA  mutations seem to be similar, our study has
revealed hundreds of differentially expressed genes that
group the tumours according to the receptor mutation sta-
tus and receptor gene expression. However, although
many of these genes may be involved in receptor-specific
alterations of GIST intracellular signalling pathways, we
identified no discriminative profiles of gene expression
associated with clinical or pathological outcomes. Most of
the discriminative genes were found to be upregulated in
PDGFRA-mutated GISTS.
To further clarify if gene signatures that group GISTs
according to KIT/PDGFRA mutation status, as described
previously [18,19], may be defined also at the level of
intracellular signalling pathways, we analyzed microarray
data in the context of functional annotation.
Among terms and pathways in the current analysis with
the highest overrepresentation in GISTs with mutated
and/or overexpressed PDGFRA were "blood vessel develop-
ment" and "angiogenesis". In fact, GISTs are highly vascu-
larised tumours, and VEGF expression has been
postulated to be a KIT-genotype-independent adverse
prognostic indicator for early treatment failure and poor
survival of GIST patients on imatinib therapy [36,37].
We also found that the functional features of genes differ-
entially expressed between the two groups of GISTs were
represented by the G-protein-coupled receptor protein
signalling pathway (GO:0007186). The regulated secre-
tion of transmitters and hormones, a characteristic event
of neuroendocrine cells and tumours, is controlled by G-
protein-coupled membrane receptors. Indirect evidence
of neural or neuroendocrine phenotypes including high
expression of this type of receptor have been described
recently in GISTs [5].
As part of this study, we compiled lists of differentially
expressed genes for comparison with lists of interacting
partners of KIT and PDGFR. This analysis identified signif-
icantly lower expression of PKC-alpha and significantly
higher expression of PKC-theta in tumours with KIT
mutations compared to those with PDGFRA mutations or
wild-type tumours. The PKC family consists of 10 related
serine/threonine protein kinases, which are involved in
regulation of cell proliferation, survival, and death. In
addition, some are considered to be tumour promoters
that may enhance multiple cellular oncogenic signalling
pathways [38,39]. While the alpha, beta, epsilon, and
atypical PKCs possess anti-apoptotic action, the delta and
theta isoforms usually promote apoptosis [40]. Interest-
ingly, PKC-theta has been selected previously as a sensi-
tive marker of GISTs [41].
The enrichment analysis based on GO or similar annota-
tions gives reliable results for sets of hundreds of genes,
and such sets are likely to be identified with microarrays
covering almost the whole transcriptome, as oligonucle-
otide microarrays which were used in this study. Experi-
ments exploiting older technologies, like those used by
Subramanian et al. [19] hold the middle ground between
traditional single-gene techniques and high-throughput
implementations and cannot provide sufficient data for
systemic interpretation.
While the noise inherent in microarray technology often
complicates the process of data interpretation, both the
array quality and the choice of analytical processing meth-
ods have a major impact on differential expression analy-
sis of microarray data [26]. Thus, stringent selection
criteria are essential for identifying differentially expressed
genes. In the case of a set of thousands of transcripts, P val-
ues and FC criteria are not sufficient if not coupled with
an adequate P value correction method for simultaneous
testing of multiple hypotheses (e.g., Bonferroni, Ben-
jamini-Hochberg). An apparent lack of such a step in the
study reported by Kang et al. (2005) is a likely reason for
low concordance with other studies. With over 4000
genes tested, a P < 0.01 criterion leads to about 40 false
positives (i.e., roughly 57% of a reported 70-gene data
set). In the current work, we sought to address these issues
through appropriate statistical adjustment for multiple
hypotheses.
Conclusion
To summarized, our study has identified novel molecular
mechanisms likely to be involved in receptor-dependent
GIST development and allowed confirmation of previ-
ously published results. These observations may be useful
for the development of molecular markers that might pre-
dict which GIST patients will experience an adequate
response to proposed therapy. However, before health-
care professionals can see benefits from molecular diag-
nostics, a full understanding of the biological processes
underlying GIST development is required.
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